Carper, colleagues raise ethics concerns over Trump administration COVID-19 response
Sens. Tom Carper, D-Delaware, Elizabeth Warren, D-Massachusetts, and Richard Blumenthal, D-Connecticut, sent a letter April 16 to the White House Designated Agency Ethics Official raising ethics concerns about the fact that President Donald Trump appears to be making decisions based on his and his advisers' financial interests and that his son-in-law and senior adviser, Jared Kushner, has reportedly been managing a "shadow task force" of select government officials and private sector actors tasked with responding to and addressing the novel coronavirus pandemic.
Carper, Warren and Blumenthal urged the DAEO to use his authority to make compliance with ethics and conflict of interest laws a priority for the White House during the pandemic.
"These reports are troubling: amidst the coronavirus pandemic, the American public should not have to worry that critical public health and economic decisions are being made in secret by public officials influenced by financial connections and personal ties," the senators wrote to Scott Gast, the White House DAEO. "You have the responsibility to make compliance with federal ethics law a priority for the White House during this pandemic."
According to a press release from Carper’s office, “Kushner's task force reportedly includes ‘a suite of McKinsey consultants,’ a private equity executive and a host of other representatives from private industries. However, the Trump administration has not disclosed who exactly comprises this task force, the vetting process for these members and what specific role the members are playing in addressing issues related to the pandemic. Moreover, Kushner and his task force appear to have had a substantial, and often disruptive, influence over a series of White House policy initiatives related to the COVID-19 pandemic, and companies with connections to Kushner appear to be benefitting from White House and administration policies and decisions. Kushner's actions make it difficult to determine if decisions are being made to advance the public interest and if all appropriate ethics precautions are being taken.”
Carper, Warren and Blumenthal also raise concerns that the personal financial interests of individuals advising Trump may be affecting White House COVID-19 decision making, in particular with regard to the use of the drug hydroxychloroquine.
According to the release, “senior government officials and well-connected, non-government donors who are, or may be, advising Trump on COVID-19 appear to have financial interests in hydroxychloroquine and the FDA's decision to issue an Emergency Use Authorization of the drug. For instance, Fisher Asset Management head Ken Fisher, who has donated to Trump, is one of the largest shareholders in a company that manufactures the brand-name version of hydroxychloroquine. Additionally, Chirag Patel, a member of one of Trump's golf clubs who has golfed with the president at least twice, is the co-founder of a generic pharmaceutical company that is ‘gearing up’ to produce the drug.”
"These potential conflicts raise obvious questions regarding whether the actions of White House and other Trump administration officials during the COVID-19 pandemic are consistent with federal criminal conflict of interest law, which prohibits a government employee from 'participating personally and substantially, on behalf of the federal government, in any particular matter in which he or she has a financial interest,’” wrote the senators.
A copy of the letter is available at bit.ly/34MqZGf.